The Products selected save producers time and reduce cost and labor, all while improving safety. Check out the 2025 winners ...
Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously (SC) ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ„¢) for vision correction, today issued the following open letter to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results